+1(781)975-1541
support-global@metwarebio.com

Oxylipin Targeted Metabolomics

Wide Coverage: Encompassing 141 compounds
Absolute Quantification: 141 standard curves with r > 0.99
High Sensitivity: Detecting at ng/ml concentrations
Rigorous Quality Control: Ensuring data reliability

Technology Introduction of Oxylipins Analysis

Oxylipins are a diverse group of bioactive lipid molecules produced through the oxidation of polyunsaturated fatty acids (PUFAs), including both omega-3 and omega-6 fatty acids, via enzymatic pathways mediated by cyclooxygenases (COXs), lipoxygenases (LOXs), and cytochrome P450 enzymes (CYPs). Oxylipins play vital roles in regulating numerous physiological processes, such as inflammation, immune response, blood flow, and cellular signaling. Depending on the type of fatty acid and the specific enzymatic pathway, oxylipins can have a variety of effects, including promoting or resolving inflammation, modulating vascular tone, and influencing cellular growth and apoptosis.
MetwareBio’s oxylipin-targeted metabolomics service provides absolute quantitative detection of 141 oxylipins using a dual-validation approach with both internal and external standards, supported by our proprietary database. This in-depth analysis covers a wide range of oxylipins, including oxidized derivatives of arachidonic acid (AA), linoleic acid (LA), gamma-linolenic acid (GLA), dihomo-gamma-linolenic acid (DGLA), alpha-linolenic acid (ALA), docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA).

Technology Introduction of Oxylipins Analysis - MetwareBio

 

Technology Superiority of Oxylipins Analysis

Wide Coverage
Encompassing 141 compounds, including oxidized derivatives of AA, LA, GLA, DGLA, ALA, DHA, and EPA.
Absolute Quantification
141 standard curves with r > 0.99 and 25 internal standards for precise measurement.
High Sensitivity
Utilizes the AB QTRAP® 6500+ LC-MS/MS, enabling detection at ng/ml concentrations.
Rigorous Quality Control
Ensuring data reliability with controls like blanks, solvents, and mixed standards.

 

Applications of Oxylipins Targeted Metabolomics

Disease Mechanism Research
This service is instrumental in investigating the underlying mechanisms of various diseases, including cardiovascular, oncological, immunological, endocrine, nephrological, gastrointestinal, and neurological disorders. By providing comprehensive oxylipin profiling, it enables researchers to uncover key metabolic pathways and molecular interactions, offering valuable insights into disease progression and potential therapeutic targets.
Drug Target Research
This service facilitates the study of drug mechanisms by identifying how therapeutic agents interact with oxylipin-related pathways. For example, aspirin exerts its anti-platelet aggregation and anti-inflammatory effects by inhibiting oxylipin-derived molecules such as thromboxane A2 (TXA2) or prostacyclin (PGI2). Such analyses support drug development by elucidating the role of oxylipins in therapeutic efficacy and identifying novel drug targets.
Disease Biomarker Discovery
This service aids in identifying potential biomarkers by analyzing differences in oxylipin profiles between healthy and diseased groups. These biomarkers can be applied to early disease diagnosis, precise classification, and prognosis prediction, enhancing clinical outcomes and advancing personalized medicine.
Health Supplement Functionality Research
This service supports the evaluation of health supplements, particularly those containing DHA and other polyunsaturated fatty acids, by analyzing their oxidized metabolites. These metabolites contribute to critical health benefits, including blood pressure regulation, inflammation reduction, and angiogenesis inhibition. Oxylipin-targeted metabolomics helps validate supplement efficacy and optimize their applications in health and wellness management.

List of Oxylipin Molecules

Index Abbreviation CAS No Class Index Abbreviation CAS No Class
1 13-HOTrE 87984-82-5 ALA 21 (±)7(8)-DiHDPE(A) - DHA
2 9(S)-HpOTrE 111004-08-1 ALA 22 (±)8-HDHA/HDoHE 90780-54-4 DHA
3 9-OxoOTrE 125559-74-2 ALA 23 DHA 6217-54-5 DHA
4 ALA 463-40-1 ALA 24 PDX 871826-47-0 DHA
5 (±)5-HETE 70608-72-9 ARA 25 RvD1 872993-05-0 DHA
6 11,12-EET 81276-02-0 ARA 26 RvD2 810668-37-2 DHA
7 11β-PGE2 38310-90-6 ARA 27 (±)17(18)-DiHETE - EPA
8 14,15-EET 81276-03-1 ARA 28 (±)18-HEPE 141110-17-0 EPA
9 15-keto-PGF2α 35850-13-6 ARA 29 17(18)-EpETE 131339-23-6 EPA
10 ARA 506-32-1 ARA 30 EPA 10417-94-4 EPA
11 LTE4 75715-89-8 ARA 31 LXA5 110657-98-2 EPA
12 LXB4 98049-69-5 ARA 32 RvE1 552830-51-0 EPA
13 PGA2 13345-50-1 ARA 33 13(S)-HOTrE(γ) 74784-20-6 GLA
14 TXB2 54397-85-2 ARA 34 GLA 506-26-3 GLA
15 8(S)-HETrE 889573-69-7 DGLA 35 (±)9-HODE 98524-19-7 LA
16 DGLA 1783-84-2 DGLA 36 13(S)-HpODE 33964-75-9 LA
17 PGD1 17968-82-0 DGLA 37 9,10-EpOME 16833-56-0 LA
18 PGE1 745-65-3 DGLA 38 9-oxoODE 54232-59-6 LA
19 TXB1 64626-32-0 DGLA 39 LA 60-33-3 LA
20 (±)19(20)-EpDPE(A) - DHA 40 5-HETrE 195061-94-0 MA
41

 

Contact for a full list.

Project Workflow of Oxylipins Targeted Metabolomics

Sample Requirement of Oxylipins Targeted Metabolomics

Sample Class Sample Type Recommended
Sample Size
Minimum Sample Size
Liquid I Plasma, Serum, Hemolymph, Whole Blood, Milk, Egg White 200 μl 100 μl
Liquid II Cerebrospinal Fluid (CSF), Interstitial Fluid (TIF), Uterine Fluid, Pancreatic Juice, Bile, Pleural Effusion, Follicular Fluid, Postmortem Fluid, Tissue Fluid, Tears, Aqueous Humor, Digestive Juices, Bone Marrow (liquid) 200 μl 100 μl
Liquid III Seminal Plasma, Amniotic Fluid, Prostatic Fluid, Rumen Fluid, Respiratory Condensate, Gastric Lavage Fluid, Bronchoalveolar Lavage Fluid (BALF), Urine, Sweat, Saliva, Sputum 500 μl 100 μl
Tissue I Small Animal Tissues, Placenta, Blood Clot, Mycelium, Nematode, Zebrafish (whole fish), Bone Marrow (solid), Nail 100 mg 20 mg
Tissue II Large Animal Tissues, Whole Insect Body, Wings (of insects), Pupa, Eggs, Large Fungi (mushroom types), Large Algae (red algae), Large Amount of Mycelium/Mycelial Balls, Cartilage, Bone (solid) 500 mg 20 mg
Tissue III Zebrafish Organs, Insect Organs, Whole Microinsect Body (e.g., Drosophila) 20 units 10 units
Solid I Feces, Intestinal Contents, Lyophilized Fecal Powder 200 mg 20 mg
Solid II Milk Powder, Microbial Fermentation Product (solid), Culture Medium (solid), Earwax, Lyophilized Tissue Powder, Feed, Egg Yolk, Lyophilized Plant Powder, Lyophilized Egg Powder 100 mg 20 mg
Solid III Honey, Nasal Mucus, Sputum 100 mg 20 mg
Solid IV Sludge, Soil 600 mg 300 mg
Cell I Adherent Cells, Animal Cell Lines 2*10^7 cells 1*10^7 cells
Cell II E. Coli, Yeast Cells 1*10^10 cells 5*10^8 cells
Cell III Small Amount of Fungal Mycelial Balls/Mycelium, Unicellular Algae (Cyanobacteria), Large Quantities of Bacterial Hyphae (sediment), Mucilaginous Protoplasmic Clusters (hyphae) 100 mg 20 mg
Organelle I Lysosomes, Mitochondria, Endoplasmic Reticulum 4×10^7 cells 1×10^7 cells
Organelle II Exosomes, Extracellular Vesicles 2×10^9 particles 1×10^9 particles
Special Sample I Skin Tape or Patch 2 pieces 1 piece
Special Sample II Test Strips 2 pieces 1 piece
Special Sample III Swab 1 piece 1 piece

Case Study

(Supported by MetwareBio's Oxylipin Targeted Metabolomics service)

Article:  Loss of Cardiac Ferritin H Facilitates Cardiomyopathy via Slc7a11-Mediated Ferroptosis


Rationale: Maintaining iron homeostasis is essential for proper cardiac function. Both iron deficiency and iron overload are associated with cardiomyopathy and heart failure via complex mechanisms. Although ferritin plays a central role in iron metabolism by storing excess cellular iron, the molecular function of ferritin in cardiomyocytes remains unknown.


Objective: To characterize the functional role of Fth (ferritin H) in mediating cardiac iron homeostasis and heart disease. 

 

Methods and Results: Mice expressing a conditional Fth knockout allele were crossed with 2 distinct Cre recombinase-expressing mouse lines, resulting in offspring that lack Fth expression specifically in myocytes (MCK-Cre) or cardiomyocytes (Myh6-Cre). Mice lacking Fth in cardiomyocytes had decreased cardiac iron levels and increased oxidative stress, resulting in mild cardiac injury upon aging. However, feeding these mice a high-iron diet caused severe cardiac injury and hypertrophic cardiomyopathy, with molecular features typical of ferroptosis, including reduced glutathione (GSH) levels and increased lipid peroxidation. Ferrostatin-1, a specific inhibitor of ferroptosis, rescued this phenotype, supporting the notion that ferroptosis plays a pathophysiological role in the heart. Finally, we found that Fth-deficient cardiomyocytes have reduced expression of the ferroptosis regulator Slc7a11, and overexpressing Slc7a11 selectively in cardiomyocytes increased GSH levels and prevented cardiac ferroptosis.


Conclusions: Our findings provide compelling evidence that ferritin plays a major role in protecting against cardiac ferroptosis and subsequent heart failure, thereby providing a possible new therapeutic target for patients at risk of developing cardiomyopathy.

 

Reference

Xu K, Huang P, Wu Y, et al. Engineered Selenium/Human Serum Albumin Nanoparticles for Efficient Targeted Treatment of Parkinson's Disease via Oral Gavage. ACS Nano. 2023;17(20):19961-19980. https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.120.316509

 

WHAT'S NEXT IN OMICS: THE METABOLOME

Please submit a detailed description of your project. We will provide you with a customized project plan metabolomics services to meet your research requests. You can also send emails directly to support-global@metwarebio.com for inquiries.
Name can't be empty
Email error!
Message can't be empty
CONTACT FOR DEMO
Name error
E-mail error
Description error
The files will be available for download after the form is submitted!
+1(781)975-1541
LET'S STAY IN TOUCH
submit
Copyright © Metware Biotechnology Inc. All Rights Reserved.
support-global@metwarebio.com +1(781)975-1541
8A Henshaw Street, Woburn, MA 01801
Contact Us Now
Name can't be empty
Email error!
Message can't be empty